Related Experiment Videos
Tumor cell motility. A novel therapeutic target in bladder carcinoma, experimental and clinical results
Abstract:
Surgery, chemotherapy and radiotherapy are the current modalities of tumor management. However, in systemic disease, predicted patients' cure can be achieved in but a few tumor diseases. Based on previous basic research we have highlighted that the loss of cell-cell adhesion in association with an increased tumor cell motility is an essential feature of the malignant potential of bladder tumors. Thus, we have attempted therapeutical methods differing from hitherto existing treatments by focusing on a tumor cell function we call cell motility. Characterization of so-called anti-motility drugs was performed biochemically as well analyzed by in vitro by using in established bladder carcinoma cell lines. We evaluated the potential therapeutic benefit in a model of chemically induced bladder carcinoma followed by a phase I/II trial applying anti-motility drugs in patients which were chemotherapy-resistant and having metastatic bladder cancer. Both basic research as well as the results of first translational clinical trials confirmed, that advanced bladder carcinomas can be favorably affected by inhibition of tumor cell motility.
Insights
Targeting tumor cell motility offers a novel therapeutic approach for advanced bladder cancer. Anti-motility drugs show promise in treating chemotherapy-resistant metastatic bladder carcinoma.
Area of Science:
- Oncology
- Cancer Biology
- Translational Medicine
Background:
- Current cancer treatments like surgery, chemotherapy, and radiotherapy have limitations in achieving cures for systemic diseases.
- Loss of cell-cell adhesion and increased tumor cell motility are key features of malignant potential in bladder tumors.
Purpose of the Study:
- To investigate novel therapeutic strategies targeting tumor cell motility in bladder cancer.
- To evaluate the efficacy of anti-motility drugs in preclinical models and clinical trials for advanced bladder carcinoma.
Main Methods:
- Biochemical characterization and in vitro analysis of anti-motility drugs using bladder carcinoma cell lines.
- Evaluation of therapeutic benefit in a chemically induced bladder carcinoma model.
- Phase I/II clinical trial of anti-motility drugs in patients with chemotherapy-resistant metastatic bladder cancer.
Main Results:
- Preclinical studies confirmed the role of cell motility in bladder tumor malignancy.
- In vitro and in vivo studies demonstrated the effectiveness of anti-motility drugs.
- Phase I/II trials indicated favorable outcomes for advanced bladder carcinomas treated with anti-motility drugs.
Conclusions:
- Inhibition of tumor cell motility is a promising therapeutic strategy for advanced bladder cancer.
- Anti-motility drugs represent a potential new treatment option for patients with metastatic and chemotherapy-resistant bladder carcinoma.